miRNA Scientific

Executive Summary

miRNA Scientific is a precision healthcare company developing non-invasive liquid biopsy solutions for cancer management, with an initial focus on urological cancers. Founded in 2018 and headquartered in San Diego, the company leverages its proprietary miR Disease Management Platform to analyze microRNA biomarkers from urine samples. Its first commercial product, the miR Sentinel™ Prostate Cancer Test, aims to reduce unnecessary biopsies by providing a high-accuracy, non-invasive alternative to current screening methods. The platform has the potential to expand into other cancer types, positioning the company as a key player in the growing liquid biopsy market, which is projected to exceed $10 billion by 2030. As a private, early-stage diagnostics firm, miRNA Scientific faces typical challenges including regulatory hurdles, clinical validation, and market adoption. However, the strong clinical need for improved prostate cancer screening—given the high false-positive rate of PSA tests—presents a significant opportunity. The company’s urine-based approach offers advantages in cost, convenience, and patient compliance over blood-based liquid biopsies. If successful in securing FDA clearance or CE marking, miRNA Scientific could capture substantial market share. The next 12–18 months are critical for demonstrating clinical utility and securing partnerships or funding to support commercialization.

Upcoming Catalysts (preview)

• Q1 2027FDA Submission for miR Sentinel Prostate Cancer Test40% success
• Q4 2026Publication of Clinical Validation Study in Peer-Reviewed Journal60% success
• Q2 2027Partnership or Distribution Agreement with Major Lab or Hospital Network35% success